Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
UTHR 
United Therapeutics Corporation (UTHR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: UTHR (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 36.49% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.96B USD | Price to earnings Ratio 12.61 | 1Y Target Price 396.46 |
Price to earnings Ratio 12.61 | 1Y Target Price 396.46 | ||
Volume (30-day avg) 571563 | Beta 0.64 | 52 Weeks Range 221.53 - 417.81 | Updated Date 03/27/2025 |
52 Weeks Range 221.53 - 417.81 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 24.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 41.53% | Operating Margin (TTM) 49.18% |
Management Effectiveness
Return on Assets (TTM) 12.44% | Return on Equity (TTM) 19.23% |
Valuation
Trailing PE 12.61 | Forward PE 11.25 | Enterprise Value 10992602855 | Price to Sales(TTM) 4.85 |
Enterprise Value 10992602855 | Price to Sales(TTM) 4.85 | ||
Enterprise Value to Revenue 3.82 | Enterprise Value to EBITDA 6.64 | Shares Outstanding 44912200 | Shares Floating 41323694 |
Shares Outstanding 44912200 | Shares Floating 41323694 | ||
Percent Insiders 1.83 | Percent Institutions 100.82 |
Analyst Ratings
Rating 3.94 | Target Price 398.02 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold 6 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
United Therapeutics Corporation
Company Overview
History and Background
United Therapeutics Corporation was founded in 1996 by Martine Rothblatt. Its initial focus was on developing treatments for pulmonary hypertension. The company has grown through internal development and acquisitions, expanding its portfolio to include other rare diseases.
Core Business Areas
- Pulmonary Hypertension: Development and commercialization of therapies for pulmonary hypertension (PH). This includes various formulations of prostacyclin analogs and other PH treatments.
- Other Rare Diseases: Development and commercialization of therapies for other rare diseases beyond PH. This includes areas such as oncology.
- Organ Manufacturing: Pioneering efforts in the field of organ manufacturing, including xenotransplantation and regenerative medicine.
Leadership and Structure
Martine Rothblatt is the Chairperson and CEO. The company has a standard corporate structure with various departments responsible for research and development, manufacturing, commercialization, and administration.
Top Products and Market Share
Key Offerings
- Remodulin: A continuously infused prostacyclin analog for pulmonary arterial hypertension (PAH). Competitors include generic prostacyclin analogs. In 2023, Remodulin generated $646.7 million in sales.
- Tyvaso: An inhaled prostacyclin analog for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Competitors include Adcirca (tadalafil) and Letairis (ambrisentan). In 2023, Tyvaso generated $1,037.4 million in sales.
- Orenitram: An oral prostacyclin analog for PAH. Competitors include other oral PAH therapies. In 2023, Orenitram generated $340.1 million in sales.
- Adcirca: An oral PDE5 inhibitor for PAH (licensed from Eli Lilly). In 2023, Adcirca generated $64.5 million in sales.
- Unituxin: An antibody therapy for high-risk neuroblastoma. Competitors include other chemotherapy regimens and supportive care. In 2023, Unituxin generated $205.6 million in sales.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the rare disease segment, is characterized by high research and development costs, regulatory hurdles, and potential for high returns. Market is dominated by large players.
Positioning
United Therapeutics Corporation is a leader in the pulmonary hypertension market and is expanding into other rare disease areas. Their competitive advantage lies in their expertise in prostacyclin analogs and their pioneering efforts in organ manufacturing.
Total Addressable Market (TAM)
The estimated TAM for pulmonary hypertension treatments is several billion USD annually. The organ manufacturing market is nascent but has the potential to be significantly larger. United Therapeutics is well positioned to capture significant share of both these TAMs due to its current dominance in PAH and progress in organ manufacturing.
Upturn SWOT Analysis
Strengths
- Established presence in the pulmonary hypertension market
- Strong expertise in prostacyclin analogs
- Pioneering efforts in organ manufacturing
- Diversified product portfolio
- History of innovation in rare diseases
Weaknesses
- Reliance on a limited number of key products
- Exposure to generic competition for some products
- High research and development costs
- Regulatory risks associated with organ manufacturing
- Concentration of revenue with few products.
Opportunities
- Expansion into new rare disease areas
- Growth of the organ manufacturing market
- Potential for new drug approvals
- Strategic acquisitions
- Growth in emerging markets
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Clinical trial failures
- Competition from larger pharmaceutical companies
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
Competitive Landscape
UTHR holds a strong position in the PAH market due to its expertise in prostacyclin analogs, but faces competition from larger pharmaceutical companies with broader portfolios and greater financial resources. Its advancements in organ manufacturing set it apart.
Major Acquisitions
SteadyMed Ltd.
- Year: 2019
- Acquisition Price (USD millions): 216
- Strategic Rationale: Acquired SteadyMed to gain access to its PatchPump technology, which is used for delivering Remodulin.
Growth Trajectory and Initiatives
Historical Growth: United Therapeutics Corporation has experienced strong revenue growth in recent years, driven by the success of Tyvaso and other key products.
Future Projections: Analysts project continued revenue growth, driven by the expansion of existing products and the potential launch of new therapies. Earnings growth is expected to be somewhat constrained by ongoing research and development investments.
Recent Initiatives: Recent initiatives include expanding the label for Tyvaso, advancing the organ manufacturing program, and developing new therapies for other rare diseases.
Summary
United Therapeutics is a relatively strong company with a leading position in pulmonary hypertension and promising organ manufacturing initiatives. Tyvaso's success and ongoing research fuel growth, but reliance on a few key products and regulatory hurdles pose risks. The company needs to continue innovating, especially in organ manufacturing to secure long-term growth, while also managing competitive pressures.
Similar Companies
- JNJ
- MRK
- LLY
- VRTX
Sources and Disclaimers
Data Sources:
- United Therapeutics Corporation SEC Filings
- Analyst Reports
- Company Website
- Various Financial Data Providers
Disclaimers:
This analysis is based on publicly available information and analyst estimates and does not constitute financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About United Therapeutics Corporation
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 1999-06-17 | Founder, Chairman & CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1305 | Website https://www.unither.com |
Full time employees 1305 | Website https://www.unither.com | ||
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.